Scienza e Tecnologia
National Institute for Health and Care Excellence (NICE) releases Medtech Innovation Briefing (MIB) for Imbio's Lung Texture Analysis Algorithm
The Briefing included a description of the LTA technology, how it is used, its potential patient and system impact, along with a review of relevant published evidence and likely costs of using the technology. Clinical experts also provided comments including:
Dr. Graham Robinson , President of the British Society of Thoracic Imaging and co-founder of Heart & Lung Imaging Ltd explains, "At the Royal United Hospital in Bath, UK and at Heart & Lung Imaging Ltd ( www.heartlunghealth.com ) we have been using Imbio's LTA for both routine clinical practice and research activity for some time. It is an exciting, intuitive and genuinely useful product in the ILD space."
"Imbio is pleased to receive support for the use of Lung Texture Analysis™ from a world-renowned source of clinical expertise such as NICE," said
Dave Hannes , CEO at Imbio. "This briefing is a great milestone for the technology and for the centers that could benefit from the added value of providing a more effective patient care path due to improved diagnostic accuracy that LTA can provide."
The NICE briefing can be accessed here: Summary | Lung Texture Analysis for Measuring Interstitial Lung Diseases | NICE
Imbio is a leader in fully-automated AI image analysis for chronic pulmonary conditions. Imbio's regulatory cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalized care for patients. Lung Texture Analysis is CE Marked and can be accessed directly through Imbio or through one of our partners such as Siemens Healthineers and Wellbeing Software . For more information, please visit www.imbio.com.
Logo - https://mma.prnewswire.com/media/1607051/Imbio_Logo.jpg